GlassScriptPhysician profile
Justin Powell Hess
NPI 1760040125
$3,641.09
in general payments reported to CMS, 2019-2025
23 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $230 · 2022: $763 · 2023: $829 · 2024: $896 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,524.02 | 2021-2025 | Clareon, Ngenuity, Hydrus Microstent |
| Sight Sciences, INC. | $223.58 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $212.71 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Rxsight INC | $202.04 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $176.68 | 2022-2023 | |
| Abbvie INC. | $152.05 | 2023-2025 | |
| Oyster Point Pharma, INC. | $150.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $139.40 | 2025 | Tecnis Iol, Tecnis Iol |
| Horizon Therapeutics Plc | $119.37 | 2022 | |
| Genentech, INC. | $104.72 | 2022 | |
| Dompe US, INC. | $100.15 | 2024-2025 | Oxervate |
| Allergan, INC. | $99.99 | 2020 | |
| Mallinckrodt Hospital Products INC. | $81.36 | 2021 | |
| Harrow Eye, LLC | $66.89 | 2025 | Iheezo |
| Carl Zeiss Meditec Cataract Technology INC. | $53.69 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $44.06 | 2022 | |
| Amgen INC. | $43.47 | 2024-2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $38.24 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Pacira Pharmaceuticals Incorporated | $35.37 | 2024 | Exparel |
| Genentech USA, INC. | $22.52 | 2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.17 | 2020 | |
| Ocular Therapeutix, INC. | $15.62 | 2025 | Dextenza |
| Biotissue Holdings INC. | $13.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.